Polen Capital Management LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 65.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,340,649 shares of the biopharmaceutical company’s stock after buying an additional 529,348 shares during the period. Regeneron Pharmaceuticals makes up about 5.4% of Polen Capital Management LLC’s portfolio, making the stock its 8th largest position. Polen Capital Management LLC owned 1.28% of Regeneron Pharmaceuticals worth $492,139,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. BlackRock Institutional Trust Company N.A. raised its stake in Regeneron Pharmaceuticals by 2.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 2,010,295 shares of the biopharmaceutical company’s stock worth $702,055,000 after buying an additional 49,006 shares during the last quarter. BlackRock Fund Advisors raised its stake in Regeneron Pharmaceuticals by 0.6% in the second quarter. BlackRock Fund Advisors now owns 2,221,959 shares of the biopharmaceutical company’s stock worth $775,975,000 after buying an additional 13,282 shares during the last quarter. BlackRock Inc. raised its stake in Regeneron Pharmaceuticals by 25.7% in the second quarter. BlackRock Inc. now owns 186,678 shares of the biopharmaceutical company’s stock worth $65,194,000 after buying an additional 38,173 shares during the last quarter. BlackRock Investment Management LLC raised its stake in Regeneron Pharmaceuticals by 136.0% in the second quarter. BlackRock Investment Management LLC now owns 403,418 shares of the biopharmaceutical company’s stock worth $140,886,000 after buying an additional 232,471 shares during the last quarter. Finally, Sustainable Growth Advisers LP raised its stake in Regeneron Pharmaceuticals by 18.4% in the second quarter. Sustainable Growth Advisers LP now owns 415,824 shares of the biopharmaceutical company’s stock worth $145,218,000 after buying an additional 64,490 shares during the last quarter. 68.83% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded down 2.86% during trading on Thursday, hitting $373.02. The company had a trading volume of 1,276,889 shares. The stock has a market capitalization of $39.34 billion, a P/E ratio of 48.45 and a beta of 1.44. The firm’s 50 day moving average is $363.34 and its 200-day moving average is $385.56. Regeneron Pharmaceuticals, Inc. has a 52 week low of $325.35 and a 52 week high of $452.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, February 9th. The biopharmaceutical company reported $3.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.03 by $0.01. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. The business earned $1.23 billion during the quarter, compared to analyst estimates of $1.30 billion. During the same quarter in the previous year, the company posted $2.83 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 11.7% on a year-over-year basis. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $13.17 EPS for the current fiscal year.

This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this story can be read at http://www.watchlistnews.com/polen-capital-management-llc-boosts-stake-in-regeneron-pharmaceuticals-inc-regn/1120904.html.

A number of research analysts have issued reports on REGN shares. RBC Capital Markets set a $626.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, December 5th. Leerink Swann set a $513.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 25th. Roth Capital set a $520.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, October 28th. Vetr upgraded Regeneron Pharmaceuticals to a “buy” rating in a research note on Monday, November 21st. Finally, Canaccord Genuity set a $450.00 price objective on Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, February 3rd. Thirteen equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $447.16.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi acquired 87,298 shares of the company’s stock in a transaction dated Wednesday, January 11th. The stock was purchased at an average price of $369.71 per share, with a total value of $32,274,943.58. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Charles A. Baker sold 3,000 shares of the company’s stock in a transaction dated Monday, December 12th. The stock was sold at an average price of $392.02, for a total value of $1,176,060.00. Following the completion of the transaction, the director now directly owns 12,000 shares of the company’s stock, valued at approximately $4,704,240. The disclosure for this sale can be found here. Insiders own 10.40% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.